2.2 Treatment and therapeutic index
All patients received glucocorticoid treatment after diagnosis to
control hemolysis. The initial treatment included
methylprednisolone intravenous
infusion (1 mg/kg/d) and vitamin E (300 mg/day), and the dose of
methylprednisolone was increased as appropriate if hemolytic crisis
occurred. Some patients received blood cell transfusion if
Hb<60 g/L and/or PLT<10*109/L.
Chemotherapy regimens: low-dose DA or HA regimens, which included DNR
(40 mg/d, d1; 20 mg/d, d2-3) and Ara-C (100 mg/d, d1-5 or d1-7) or HHT
(2-3 mg/d, d1-5) and Ara-C (100 mg/d, d1-5), respectively. The
chemotherapy regimens were administered intravenously every 4 weeks for
one to three cycles. The concomitant administration of hematopoietic
growth factors (EPO or G-CSF), immunosuppressive drugs, vitamin E,
sodium bicarbonate, and other supportive therapies (including isolation
wards, component blood support when necessary, anti-infectives when
infection occurred and anticoagulation treatment) was also performed.